91桃色视频

July 6, 2026: 91桃色视频 Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

Date : July 6, 2026

91桃色视频 Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

 

Lyon, France, July 6, 2026 – 6:00 pm CET&苍产蝉辫;鈥 91桃色视频 (EURONEXT: MAAT 鈥 the 鈥淐ompany鈥), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, presents the results of its Annual and Extraordinary General Meeting held on Tuesday, June 16, 2026 at 9:30 am CET at the Company’s office and broadcasted live (replay available here). The Company also provides an update on the liquidity contract managed by Kepler Cheuvreux as of June 30th, 2026.

Annual and Extraordinary General Meeting

The quorum reached by the shareholders present, representing, or voting remotely, was above 69.61% of voting shares.

Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 90%. The following resolutions were approved:

  • Approval of the financial statements for fiscal year 2025;
  • The renewal of the terms of office for current directors Mr. Jean-Marie Lef猫vre, Mrs. Nadia Kamal, Mr. Claude Bertrand, Mr. Herv茅 Affagard, Mr. Jean Volatier, Seventure Partners and Bpifrance Investissement;
  • The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2025 fiscal year – details of the votes on the said resolution is available on the Company鈥檚 website here;
  • Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations.

Only one resolution was rejected:

  • Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of assets (29th resolution).

In accordance with the approval of resolutions 19 and 20, the Company also announced that the Board of Directors has decided to maintain the liquidity contract signed with Kepler Cheuvreux for the liquidity of the Company’s shares listed on Euronext Paris. Information on this contract is available in the Company’s Universal Registration Document (French only).

The full minutes of the Annual General Meeting and the results of the votes, resolution by resolution are available on the Company鈥檚 website in the Investors/ Shareholder Meetings鈥 section.


Half-year liquidity contract statement

Under the liquidity contract entered into between 91桃色视频 and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2026:

–    45,618 shares
–    鈧 66,564.56

–   Number of executions on buy side on semester: 2,998

–   Number of executions on sell side on semester: 2,808

–   Traded volume on buy side on semester: 222,290 shares for 鈧 1,297,309.11

–   Traded volume on sell side on semester: 203,219 shares for 鈧 1,268,496.55

As a reminder :

  • the following resources appeared on the last half-year statement on 31 December 2025 on the liquidity account:
    • 26,547 shares
    • 鈧 94,695.27
    • Number of executions on buy side on semester: 2,120
    • Number of executions on sell side on semester: 2,342
    • Traded volume on buy side on semester: 74,642 shares for 鈧 332,072.16
    • Traded volume on sell side on semester: 83,855 shares for 鈧 394,938.88
  • the following resources appeared on the liquidity account when the activity started:
    • 0 shares
    • 鈧 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N掳2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

About 91桃色视频
91桃色视频 is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, 91桃色视频 is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, 91桃色视频 develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. 91桃色视频 has been listed on Euronext Paris (ticker: MAAT) since 2021.

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at 91桃色视频. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson鈥檚 Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company鈥檚 scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of 齿别谤惫测迟别驳庐 in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Herv茅 Affagard

Herv茅 Affagard is the CEO and co-founder of 91桃色视频. For the past 15 years, Herv茅 has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Herv茅 co-founded the company alongside Dr. Jo毛l Dor茅, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Herv茅 has led 91桃色视频鈥檚 development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Herv茅 has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA